DB
PTGX icon

Danske Bank’s Protagonist Therapeutics PTGX Stock Holding History

Danske Bank’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$8.73K – 1476
2025
Q4 		$8.73K Hold
100
– – ﹤0.01% 1329
2025
Q3 		$6.64K Hold
100
– – ﹤0.01% 1295
2025
Q2 		$5.53K Hold
100
– – ﹤0.01% 1337
2025
Q1 		$4.84K Hold
100
– – ﹤0.01% 1184
2024
Q4 		$3.86K Sell
100
-300
-75% -$13.1K ﹤0.01% 1223
2024
Q3 		$18K Buy
+400
New +$16.2K ﹤0.01% 1346

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Danske Bank's PTGX Position: Q1 2026 in Review

Danske Bank sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 100 shares — an estimated $8.73K sold.

Danske Bank first reported a position in PTGX in Q3 2024 and held it in 6 quarters. The position peaked at $18K in Q3 2024. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Danske Bank reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Danske Bank sold 100 Protagonist Therapeutics shares in Q1 2026, an estimated $8.73K.
  • Danske Bank first reported a position in Protagonist Therapeutics in Q3 2024 and held it in 6 quarters.
  • Danske Bank's Protagonist Therapeutics position peaked at $18K in Q3 2024.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.